Health Canada has approved Cibinqo for mod. to sev. AD in patients aged ≥12yrs. incl. the relief of pruritus who have had an inadequate response to other systemic drugs or for whom these treatments are not advisable. Cibinqo can be used with/out medicated topical therapies for AD
The physical symptoms include broken skin, dry skin all over, constant itching, redness, extensive skin thickening, oozing & cracking in those with AD frequently has psycho-social problems such as anxiety, insomnia & despair. Without appropriate care, the symptoms may worsen & have a detrimental influence on a patient’s sleep habits & overall QoL
Cibinqo has received marketing authorization in the EU, Great Britain, Japan, Korea, the United Arab Emirates, Norway, Iceland, & Singapore
Ref: Newswire | Image: Pfizer
